Search results
Nisa Investment Advisors LLC Has $29,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
ETF DAILY NEWS· 6 days agoNisa Investment Advisors LLC lifted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 10,740.0% during the fourth quarter, according to its most recent 13F filing with ...
Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Mirae Asset Global Investments Co. Ltd.
ETF DAILY NEWS· 4 days agoMirae Asset Global Investments Co. Ltd. grew its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 5.7% during the 4th quarter, according to its most recent Form 13F filing with the ...
Analysis identifies 50 new genomic regions associated with kidney cancer risk
Medical Xpress· 3 days agoIn a new analysis of genetic susceptibility to kidney cancer, an international team of researchers has identified 50 new areas across the genome that are associated with the risk of developing ...
Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
WCMH Columbus· 4 days agoFirst-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced...
The Top 3 Biotech Stocks to Buy in April 2024
InvestorPlace· 2 days agoBiotech stocks are notorious for being some of the most volatile and unpredictable on the market. With clinical trials and FDA approvals creating...
Merck highlights progress on HIV, hypertension, cervical cancer drugs
WFMZ Eastern Pennsylvania and Western New Jersey· 3 days agoMerck got off to an excellent start in the first quarter of 2024. Wall Street met the news with...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 6 days agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine,...
Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
Morningstar· 4 days agoShanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Cancer drug trial provides lessons for future
Medical Xpress· 3 days agoA cancer drug was found to be ineffective in preventing recurrence of kidney cancer in patients who recently underwent tumor removal surgery, according to a clinical trial published in the Journal ...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 7 days agoKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its ...
